sacituzumab govitecan hziy
Sponsor Gilead Sciences, INC. · listed as GILD
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
Next catalyst
Event typeREADOUT
Expected date2026-12-31
As disclosedDec 2026
Date precisionmonth
Confidencemedium
Trial & sponsor
Trial (NCT)NCT04639986
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorGilead Sciences
Listed asGILD
Condition(s)Metastatic Breast Cancer
All tracked catalysts for sacituzumab govitecan hziy
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2026-12-31 | READOUT | medium | NCT04639986 |
| 2027-02-28 | READOUT | medium | NCT05382286 |
| 2027-06-30 | READOUT | medium | NCT05633654 |
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More GILD catalysts